Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the Lilly Medical website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical

  1. Medical Information Right
  2. Obesity Right
  3. Zepbound (tirzepatide) injection Right
  4. Are there safety or efficacy differences between Zepbound® (tirzepatide) injections in the abdomen versus thigh versus upper arm?
Search Zepbound (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Zepbound ® (tirzepatide) injection

2.5 mg/ 5 mg/ 7.5 mg/ 10 mg/ 12.5 mg/ 15 mg

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

Are there safety or efficacy differences between Zepbound® (tirzepatide) injections in the abdomen versus thigh versus upper arm?

Similar exposure to tirzepatide was achieved after subcutaneous injection in the abdomen, thigh, or upper arm. There is no data from studies comparing these injection sites to assess efficacy and safety differences.

US_cFAQ_TZPCWM131_EFFICACY_SAFETY_BETWEEN_INJECTION_SITE_T2D_CWM
US_cFAQ_TZPCWM131_EFFICACY_SAFETY_BETWEEN_INJECTION_SITE_T2D_CWMen-US

See important safety information, including boxed warning, in the attached prescribing information.

Tirzepatide should be injected under the skin (subcutaneously) of the stomach (abdomen), thigh, or upper arm.1

During studies, similar amounts of tirzepatide were found in the body after subcutaneous injection in the abdomen, thigh, or upper arm.1

Eli Lilly and Company cannot comment on safety and efficacy differences when using one approved injection site versus another because this has not been studied.

Patients should consult with their health care providers if they have questions about which of the approved injection site(s) is best. Health care providers may consider the patient's individual factors and medical history.

Enclosed Prescribing Information

ZEPBOUND® (tirzepatide) injection, for subcutaneous use, Lilly

Reference

1Zepbound [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.

Date of Last Review: December 19, 2024

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Consumer Health Privacy Notice
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.44 4/2025 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2025. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    California Consumer Privacy Act (CCPA) Opt-Out Icon Your Privacy Choices
    Cookie Settings
    facebook twitter linkedin
    visit www.phactmi.org
    Lilly